Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adagio Medical HoldingsADGM -9.22%10 EV-to-EBIT is -1.31 as of Aug. 25, 2026. GuruFocus rates ADGM with a GF Score™ of 10/100. The stock has 1 warning sign investors should review. Among 476 Medical Devices & Instruments companies, Adagio Medical Holdings ranks worse than 210083.82% on this metric.
Adagio Medical Holdings (NAS:ADGM) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Adagio Medical Holdings's Enterprise Value for the quarter that ended in Jun. 2026 was $32.73 Mil.
Adagio Medical Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adagio Medical Holdings EV-to-EBIT Related Terms
Adagio Medical Holdings EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Adagio Medical Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adagio Medical Holdings EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Adagio Medical Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Adagio Medical Holdings's EV-to-EBIT falls into.
Adagio Medical Holdings's current Enterprise Value is $31.37 Mil.
Adagio Medical Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adagio Medical Holdings (ADGM) has a EV-to-EBIT of -1.31 as of Aug. 25, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Adagio Medical Holdings and its competitors. According to the industry distribution chart, Adagio Medical Holdings ranks #999999 out of 476 companies in the Medical Devices & Instruments industry.
Is Adagio Medical Holdings' EV-to-EBIT too high?
Adagio Medical Holdings' current EV-to-EBIT is -1.31. Based on the distribution chart, Adagio Medical Holdings ranks #999999 out of 476 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Adagio Medical Holdings has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Adagio Medical Holdings' EV-to-EBIT compare to NXL and ICCM?
According to the Medical Devices & Instruments industry distribution chart, Adagio Medical Holdings ranks #999999 out of 476 companies for EV-to-EBIT. This places Adagio Medical Holdings in the lower half of its industry. The industry median EV-to-EBIT is 19.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.00, based on 476 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Adagio Medical Holdings and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adagio Medical Holdings's current EV-to-EBIT is -1.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adagio Medical Holdings stock overvalued right now?
Adagio Medical Holdings (ADGM) has a current EV-to-EBIT of -1.31. The current EV-to-EBIT is -1.31. Adagio Medical Holdings' overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Adagio Medical Holdings (ADGM), the current EV-to-EBIT is -1.31 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adagio Medical Holdings Inc is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias with its proprietary, catheter-based Ultra-Low Temperature Ablation (ULTA) technology. UTLA is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The company is currently focused on the treatment of ventricular tachycardia (VT), a rapid, abnormal heart rhythm, or arrhythmia, that originates in the heart's lower chambers, or ventricles. The company has one reportable segment.
10GF Score
Get the complete analysis for ADGM
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADGM has been successfully added to your 
